Purpose: To investigate the correlation between SUVmax of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no LN metastasis. Materials and Methods: This retrospective study investigated 75 patients (mean age 58.9 years; age range 30 -82 years) with invasive breast cancer who underwent FDG-PET/CT for preoperative staging. All patients underwent subsequent surgery without prior neoadjuvant chemotherapy or endocrine therapy, and those who were confirmed to have T1-or T2-stage by histopathology with no LN metastasis were included. Two patients who had no perceptible FDG accumulation on PET/CT scans were excluded. The correlations between the SUVmax of the tumor and the pathological and immunohistochemical data were evaluated. Results: The mean SUVmax for the total 73 tumors was 5.46 ± 4.05. The mean SUVmax was 3.95 ± 3.28 for the T1 stage group (n = 36) and 7.23 ± 4.10 (p < 0.001) for the T2 stage group (n = 37). A high SUVmax was significantly associated with high nuclear grade (p < 0.001), negative hormone receptor status (p < 0.001), positive HER2 status (p = 0.008), and high Ki-67 status (p < 0.001), respectively. Conclusion: In T1-T2 breast cancer with no LN metastasis, the SUVmax of FDG-PET/CT had significant positive relationships with several prognostic parameters of pathological status. Even in early-stage breast cancer patients, pretreatment FDG-PET/CT is useful for predicting malignant behavior and prognosis).
Introduction
Breast cancer is a heterogeneous disease. As a result of gene expression analysis, breast cancer is now classified into several different subtypes [1] , which is useful for predicting response to treatments [2] [3] . Furthermore, accurate initial staging of patients with breast cancer is essential for providing a precise prognosis and choosing optimal therapies. The primary tumor, lymph node, and metastasis (TNM) staging using a multimodality approach is the most important factor of prognosis and therapeutic planning. 18 F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has been widely used for initial staging, restaging of recurrence, and monitoring of the therapeutic response in oncology patients and has become the standard imaging tool for several types of cancer. FDG-PET/CT, which demonstrates the high proliferation potential of cancer cells as increased accumulation, has emerged as a useful imaging tool for staging, evaluating the treatment response, and predicting the prognosis of malignant tumors. This diagnostic modality has also been used not only to detect cancer but also to evaluate the proliferative activity and/or malignancy grades of specific types of tumors [4] [5] [6] [7] .
As for breast cancer, the practicality of FDG-PET/CT for diagnosis and staging has been established after decades of research and clinical experience, and recent interest has also focused on the prognostic value of FDG-PET/CT. A number of studies have demonstrated a correlation between FDG accumulation on PET/CT and pathological characteristics. The maximum standardized uptake value (SUVmax) can be an independent prognostic factor, and high levels of FDG accumulation indicate more aggressive proliferation potential in breast cancers [8] - [13] . Moreover, several authors have demonstrated that FDG accumulation might be a good predictor for HER2 overexpressing and triple-negative molecular subtypes [12] [13] [14] [15] .
Since most studies of PET/CT have used it in cases of large and/or locally advanced breast cancers, its practicality in the early stages, such as small and node-negative breast cancers, remains unknown. Therefore, the prognostic value of SUVmax in these patients has not been fully assessed. The purpose of this study was to assess the correlation between SUVmax on FDG-PET/CT and pathological findings, including prognostic factors, in early-stage breast cancer patients with no lymph node metastasis.
Materials and Methods

Patient Selection
This retrospective study was conducted in accordance with the regulations of the Institutional Review Board, and informed consent was obtained from all patients for access to their histopathological data.
Between January 2012 and December 2015, 698 patients with primary breast cancer underwent curative surgery. Of these, the records of pathologically prov- 
FDG-PET/CT Imaging
All 75 patients in this study underwent FDG-PET/CT. Patients fasted for at least 6 hours before the examination, and 4.0 MBq/kg Co-registered PET/CT scans were displayed using a standard gray scale for the CT images and a colored scale for the PET data, and fused images were available for review in the axial, coronal and sagittal planes, and in maximum-intensity projection 3-dimensional cine mode.
Imaging Analysis
The image data were stored on an image server (WE View, Hitachi, Japan) and interpreted on an image viewer (Natural VIEW, Hitachi, Japan). PET/CT images were interpreted by two nuclear medicine specialists (with 10 and 12 years of experience in PET) without knowledge of the preexisting radiology results and pathological findings, other than the patients had invasive breast cancer; the diagnoses of the patients were confirmed by mutual agreement. SUVmax was measured in the transaxial PET images for quantitative analysis of FDG accumulation. Regions of interest were drawn on each primary breast tumor in the FDG-PET images and SUVmax was obtained.
Histological Evaluation
The final diagnosis was histologically confirmed from specimens obtained at 
Molecular Classification of Groups
According 
Statistical Analysis
The correlations between the SUVmax of the breast cancer and the pathological and immunohistological data were evaluated using the Mann-Whitney U test (two variables) and single-factor analysis of variance and a multiple comparison test for parametric data. Receiver operating characteristic (ROC) curve analysis was performed to examine which subgroups could be differentiated from the others on the basis of SUVmax. The diagnostic accuracy of the optimal cut-off value for differentiating one subgroup from the others was also determined by ROC analysis. The data were analyzed using SPSS software (version 20, SPSS Inc., Chicago, IL, USA). Statistical significance was defined as p < 0.05.
Results
PET/CT depicted T1-T2 breast cancers with no LN metastasis in 73 (97%) of the 75 patients. Finally, a total of 73 breast cancers in 73 patients (mean age, 58.9
years; age range, 30 -82 years) were analyzed. We excluded two breast cancers (Table 3) .
PET/CT imaging of representative patients is shown in Figure 1 and Figure 2 .
Discussion
In this study, we assessed the correlation between SUVmax on FDG-PET/CT In breast cancer patients, the use of PET/CT for assessing both local extent and distant metastatic disease has been investigated. For assessment of local disease, MRI seems to be a better choice due to its higher resolution and ability to detect intra-ductal disease [17] . It should be noted that PET/CT is inferior to MRI for PET/CT is inferior to MRI for assessing the local extent of the tumor.
PET/CT may be helpful for diagnosing axillary disease, but unfortunately its sensitivity is low, i.e. less than 70% for axillary involvement. For detection of distant metastasis, however, PET/CT might be superior to conventional imaging methods [17] . PET and PET/CT may lead to upstaging of 9% -30% of breast cancer patients [18] . However, the value of PET/CT for detecting distant disease in patients with early-stage breast cancers has been questioned. In a recent study including 178 newly diagnosed breast cancer patients with no clinical evidence of LN metastasis, PET/CT resulted in a change of the treatment plan in only 3.9% of the patients, and only 2 patients (1.1%) had extra-axillary metastasis [19] . Garami In this study we excluded two breast cancers (2.7%) with no focal FDG accumulation on PET/CT. These false negative cases were T1b (of 9 mm) and T1c (of 12 mm) IDCs. Among the clinicopathological factors reported to be associated with false negative FDG accumulation in primary breast cancer, only tumor size (≤10 mm) and low tumor grade showed independent associations [13] . A small lesion size with a relatively low tumor glucose metabolic activity and a partial volume effect might explain these results [24] . Use of FDG-PET/CT for detection of the primary tumor is currently not recommended, mainly because of the supposedly low sensitivity for small carcinomas. However, the introduction of TOF technology used in this research has further increased the image quality of PET/CT and dramatically improved cancer detectability [25] . In a recent study, 67% of T1b and 98% of T1c tumors could be visualized with PET/CT. In addition, PET image acquisition can be adapted to the specific situation of the breasts and regional nodes using optimal image reconstruction [26] .
Various new imaging technologies have been developed, and the following modalities are predicted to have potential utility for breast cancer diagnosis.
Combined PET and MR systems (PET/MR) have emerged as promising imaging modalities. MR is very sensitive and PET may offer specificity. In a feasibility study, multi-parametric FDG-PET/MR improved the differentiation of tumor characteristics, possibly providing additional information for preoperative assessment [27] . In addition to increased spatial resolution, new and more specific markers for breast cancer are being developed in order to improve the value of FDG-PET/CT results. Among these new markers, attention should be drawn to 18 F-16-alpha-17-beta-fluoroestradiol and 68 Gatrastuzumab, which can non-invasively depict the tumor expression of estrogen and HER2 receptors, respectively, with potential usefulness for assessment of therapeutic planning and response [28] .
Our study had several limitations. First, it had a retrospective design and was conducted at a single institution, which would have unavoidably introduced selection bias. Second, the determination of subtype based on immunohistochemistry might not correspond to the molecular subtype in the gene expression pro- 
Conclusion
Our study demonstrates that the SUVmax value on FDG-PET/CT is shown to have significant positive relationships with several parameters of pathological status in patients with T1-T2 breast cancer but no LN metastasis. A higher SUVmax is evident in more biologically aggressive tumors. Even in early-stage breast cancer patients, FDG-PET/CT of the pre-treatment is useful for providing additional information and predicting malignant behavior and prognosis.
